MiNK Therapeutics Presents Clinical Activity And Long-Term Persistence Of Allogeneic iNKT Cells In Solid Tumors At SITC 2023
Portfolio Pulse from Benzinga Newsdesk
MiNK Therapeutics, Inc. (NASDAQ:INKT) presented new data on its agenT-797 therapy for solid tumor cancers at the Society for Immunotherapy of Cancer's annual meeting. The therapy showed clinical responses and long-term persistence without toxic pre-conditioning. AgenT-797 is advancing in a randomized phase 2 trial in 2L gastric cancer. The company also plans to launch a randomized phase 2 trial in 2L gastric cancer by the end of 2023.
November 03, 2023 | 4:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MiNK Therapeutics' agenT-797 therapy shows promising results in treating solid tumor cancers. The therapy is advancing in a phase 2 trial and another phase 2 trial is expected to launch by the end of 2023.
The news about the promising results of MiNK Therapeutics' agenT-797 therapy in treating solid tumor cancers is directly related to the company. The advancement of the therapy in a phase 2 trial and the expected launch of another phase 2 trial by the end of 2023 could potentially boost the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100